-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that, on February 2, 2023, it granted an option to purchase 1,093,831 shares of Jasper's voting common stock (the "True-Up Option") to Ronald Martell, Jasper's President and Chief Executive Officer. The True-Up Option was granted pursuant to the employment agreement, dated as of February 25, 2022, between Jasper and Mr. Martell, which provided that if Jasper closed an equity financing of at least $50 million, then promptly following the closing of such financing, and subject to approval by the Board of Directors of the Company or the Compensation Committee thereof, Mr. Martell would be granted an option to purchase 1.0% of the outstanding shares of the Company's common stock. As previously announced, on January 27, 2023, Jasper consummated an underwritten public offering of 69,000,000 shares of its common stock, at a public offering price of $1.50, for gross proceeds from such offering of approximately $103.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Jasper, satisfying the criteria for granting the True-Up Option. The True-Up Option was granted pursuant to the Jasper 2022 Inducement Equity Incentive Plan, approved by the compensation committee of Jasper's board of directors on March 14, 2022, and granted as an inducement material to Mr. Martell's employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4).
The True-Up Option has an exercise price of $1.78 per share and will vest over four years, with 25% of the total number of shares subject to the True-Up Option vesting on February 2, 2024 and 1/48th of the total number of shares subject to the True-Up Option vesting monthly thereafter, subject in each case to Mr. Martell's continued service to Jasper on each vesting date.
Jasper is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at .
Forward-looking Statements
This press release includes forward-looking statements, including statements regarding Jasper's employees and equity plans. These forward-looking statements are based upon information that is currently available to Jasper, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with Jasper's employees and equity plans, and additional risks set forth in Jasper's filings with the Securities and Exchange Commission. Jasper expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Contacts:
John Mullaly (investors)
LifeSci Advisors
617-429-3548
jmullaly@lifesciadvisors.com
Jeet Mahal (investors)
Jasper Therapeutics
650-549-1403
jmahal@jaspertherapeutics.com
Lauren Barbiero (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that, on February 2, 2023, it granted an option to purchase 1,093,831 shares of Jasper's voting common stock (the "True-Up Option") to Ronald Martell, Jasper's President and Chief Executive Officer. The True-Up Option was granted pursuant to the employment agreement, dated as of February 25, 2022, between Jasper and Mr. Martell, which provided that if Jasper closed an equity financing of at least $50 million, then promptly following the closing of such financing, and subject to approval by the Board of Directors of the Company or the Compensation Committee thereof, Mr. Martell would be granted an option to purchase 1.0% of the outstanding shares of the Company's common stock. As previously announced, on January 27, 2023, Jasper consummated an underwritten public offering of 69,000,000 shares of its common stock, at a public offering price of $1.50, for gross proceeds from such offering of approximately $103.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Jasper, satisfying the criteria for granting the True-Up Option. The True-Up Option was granted pursuant to the Jasper 2022 Inducement Equity Incentive Plan, approved by the compensation committee of Jasper's board of directors on March 14, 2022, and granted as an inducement material to Mr. Martell's employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亚州雷德伍德城,2023 年 2 月 3 日(GLOBE NEWSWIRE)——专注于开发靶向 c-kit (CD117) 的新型抗体疗法的生物技术公司 Jasper Therapeutics, Inc.(纳斯达克股票代码:JSPR)(“Jasper”)今天宣布,2023年2月2日,它向贾斯珀总裁罗纳德·马爹利授予了购买贾斯珀有表决权普通股1,093,831股的期权(“True-up期权”)和首席执行官。True-up期权是根据贾斯珀与马爹利先生于2022年2月25日签订的雇佣协议授予的,该协议规定,如果贾斯珀完成了至少5000万美元的股权融资,则在该融资结束后,经公司董事会或其薪酬委员会批准,马爹利将获得购买公司1.0%已发行普通股的选择权。正如先前宣布的那样,贾斯珀于2023年1月27日完成了69,000,000股普通股的承销公开发行,公开发行价格为1.50美元,本次发行的总收益约为1.035亿美元,扣除承保折扣和佣金以及贾斯珀应支付的其他发行费用,符合授予True-up期权的标准。Trueup期权是根据Jasper 2022年激励股权激励计划授予的,该计划于2022年3月14日获得贾斯珀董事会薪酬委员会的批准,并根据纳斯达克上市规则5635(c)(4)作为激励材料授予马爹利先生在贾斯珀工作。
The True-Up Option has an exercise price of $1.78 per share and will vest over four years, with 25% of the total number of shares subject to the True-Up Option vesting on February 2, 2024 and 1/48th of the total number of shares subject to the True-Up Option vesting monthly thereafter, subject in each case to Mr. Martell's continued service to Jasper on each vesting date.
True-up期权的行使价为每股1.78美元,将在四年内归属,受True-up期权约束的股票总数的25%将于2024年2月2日和48日归属第四 此后每月授予Trueup期权约束的股票总数,每种情况都取决于马爹利先生在每个归属日继续向贾斯珀提供服务。
Jasper is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
贾斯珀是根据纳斯达克上市规则5635(c)(4)提供这些信息的。
About Jasper
关于贾斯珀
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at .
Jasper 是一家临床阶段的生物技术公司,正在开发briquilimab,一种靶向 c-kit (CD117) 的单克隆抗体,用于治疗慢性荨麻疹和中低风险骨髓增生异常综合征 (MDS) 等慢性肥大细胞和干细胞疾病,并用作干细胞移植的调理剂,例如镰状细胞病 (SCD)、范科尼贫血 (FA) 和严重综合症免疫缺陷(SCID)。迄今为止,briquilimab在超过130名给药受试者和健康志愿者中具有明显的疗效和安全性,作为SCID、急性髓系白血病(AML)、MDS、FA和SCD的调理剂具有临床疗效。此外,briquilimab作为一种用于基因治疗的转化性非基因毒性调理剂正在开发中。欲了解更多信息,请访问我们。
Forward-looking Statements
前瞻性陈述
This press release includes forward-looking statements, including statements regarding Jasper's employees and equity plans. These forward-looking statements are based upon information that is currently available to Jasper, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with Jasper's employees and equity plans, and additional risks set forth in Jasper's filings with the Securities and Exchange Commission. Jasper expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
本新闻稿包括前瞻性陈述,包括有关贾斯珀员工和股权计划的声明。这些前瞻性陈述基于贾斯珀目前获得的信息,仅代表截至本文发布之日,并受许多风险和不确定性的影响,包括与贾斯珀员工和股权计划相关的风险,以及贾斯珀向美国证券交易委员会提交的文件中列出的其他风险。贾斯珀明确表示不承担任何义务,除非法律要求,也不承诺更新或修改任何此类前瞻性陈述。
Contacts:
联系人:
John Mullaly (investors)
LifeSci Advisors
617-429-3548
jmullaly@lifesciadvisors.com
约翰·穆拉利(投资者)
生命科学顾问
617-429-3548
jmullaly@lifesciadvisors.com
Jeet Mahal (investors)
Jasper Therapeutics
650-549-1403
jmahal@jaspertherapeutics.com
Jeet Mahal(投资者)
贾斯珀疗法
650-549-1403
jmahal@jaspertherapeutics.com
Lauren Barbiero (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com
劳伦·巴比罗(媒体)
真正的化学
646-564-2156
lbarbiero@realchemistry.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧